sharky Monday, 02/10/20 07:20:48 PM Re: None Post # of 3592 MRNA Moderna currently has nine development candidates in its prophylactic vaccines modality, including: Vaccines against serious respiratory infections • Respiratory syncytial virus (RSV) vaccine for older adults (mRNA-1777 and mRNA-1172 or V172 with Merck) • RSV vaccine for young children (mRNA-1345) • Human metapneumovirus and parainfluenza virus type 3 (hMPV/PIV3) vaccine (mRNA-1653) • Novel coronavirus (2019-nCoV) vaccine (mRNA-1273) • Influenza H7N9 (mRNA-1851) Vaccines against serious infections transmitted from mother to baby • Cytomegalovirus (CMV) vaccine (mRNA-1647) • Zika vaccine (mRNA-1893) with the Biomedical Advanced Research and Development Authority (BARDA) Vaccines against common viral infections with high unmet need • Epstein-Barr virus (EBV) vaccine (mRNA-1189) To date, Moderna has demonstrated positive Phase 1 data readouts for six prophylactic vaccines (H10N8, H7N9, RSV, chikungunya virus, hMPV/PIV3 and CMV). Moderna’s CMV vaccine is currently in a Phase 2 dose-confirmation study. Moderna’s investigational Zika vaccine (mRNA-1893), currently in a Phase 1 study, was granted FDA Fast Track designation. Moderna has built a fully integrated manufacturing plant in Norwood, MA which enables the promise of the technology platform. $MRNA Surrounded by thieves, lets fight our way out!